Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder

Nur Seda Gülcü Üstün; Ali Karayağmurlu

doi:10.17826/cumj.1121992

TR EN

Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder

Öz

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder commencing before the age of 12 years and characterized by developmentally inappropriate inattention, hyperactivity, and/or impulsivity symptoms. Stimulants such as methylphenidate (MPH) are used as first-line therapy for children with ADHD. Psychostimulants may be associated with vascular problems. Raynaud’s phenomenon (RP) is a peripheral vasculopathy potentially associated with connective tissue diseases characterized by recurring reversible vasospasm attacks triggered by cold and emotional stress. Several cases have been published involving RP observed with MPH. The present report discusses a 14-year-old girl with ADHD who experienced RP with the addition of 10 mg modified-release MPH during 27 mg osmotic release (OROS)-MPH therapy, but not during 36 mg OROS-MPH therapy.

Anahtar Kelimeler

ADHD, methylphenidate, raynaud phenomena

Kaynakça

REFERENCES 1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. Ercan ES, Polanczyk G, Akyol Ardıc U, Yuce D, Karacetın G, Tufan AE, Tekden M. (2019). The prevalence of childhood psychopathology in Turkey: a cross-sectional multicenter nationwide study (EPICPAT-T). Nordic journal of psychiatry, 73(2), 132-140.
3. Golmirzaei J, Mahboobi H, Yazdanparast M, Mushtaq G, A Kamal M, Hamzei E. (2016). Psychopharmacology of attention-deficit hyperactivity disorder: effects and side effects. Current pharmaceutical design, 22(5), 590-594.
4. de Sousa ADF, Coimbra IM, Castanho JM, Polanczyk GV, Rohde LA. (2020). EXTERNALIZING DISORDERS.Chapter D.1:1-28.
5. Cantu C, Arauz A, Murillo Bonilla LM, López M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34(7):1667–72.
6. Jefferson HJ, Jayne DR Peripheral vasculopathy and nephropathy in association with phentermine. Nephrol Dial Transplant. 1999;14(7):1761–3.
7. Kokkinos J, Levine SR. Possible association of ischemic stroke with phenteramine. Stroke. 1993;24:310 –313.
8. Karayagmurlu A, Coskun M. (2020). Successful management of methylphenidate or atomoxetine-related priapism during attention-deficit hyperactivity disorder treatment. Journal of Clinical Psychopharmacology, 40(3), 314-315.
9. Prete M, Fatone MC, Favoino E, Perosa F. Raynaud’s phenomenon: From molecular pathogenesis to therapy. Autoimmun Rev [Internet]. 2014;13(6):655–67.
10. Jones GT, Herrick AL, Woodham SE et al. Occurrence of Raynaud’s phenomenon in children ages 12– 15 years: prevalence and association with other common symptoms. Arthritis Rheum 2003;48:3518–3521.)

11. Herrick AL: Pathogenesis of Raynaud’s phenomenon. Rheumatology (Oxford) 44:587–596, 2005.
12. Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J Clin Rheumatol. 2008;14(1):30–3.
13. Yu ZJ, Parker-Kotler C, Tran K, Weller RA, Weller EB. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2010;12(2):111–5.
14. Ferahkaya H, Akça ÖF. Methylphenidate-Induced Raynaud’s Phenomenon In Two Cases With Attention-Deficit/Hyperactivity Disorder. Journal of Contemporary Medicine, 11(3 (Forthcoming Issue-Gelecek Sayı)), 1-2.
15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245, 1981.
16. Goldman W, Seltzer R, Reuman P: Association between treatment with central nervous system stimulants and Raynaud’s syndrome in children. Arthritis Rheum 58:563–566, 2008.
17. Bayram Ö, Hergüner S. OROS-methylphenidate-induced Raynaud’s phenomenon: A dose-related side effect. J Child Adolesc Psychopharmacol. 2015;25(6):521–2.
18. Meridor K, Levy Y. (2020). Systemic sclerosis induced by CNS stimulants for ADHD: a case series and review of the literature. Autoimmunity reviews, 19(1), 102439.
19. Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol 2016;82:6–16. https://doi.org/10.1111/bcp.12912.
20. Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–70.
21. Monteerarat Y, Pariwatcharakul P. (2019). Methylphenidate-Induced Raynaud Phenomenon Developed After Increasing Methylphenidate in an Adult With Attention-Deficit Hyperactivity Disorder. Journal of clinical psychopharmacology, 39(2), 178-179.)

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Tıp Bilimleri

Bölüm

Editöre Mektup

Yazarlar

Nur Seda Gülcü Üstün ^*
0000-0003-2278-9674
Türkiye

Ali Karayağmurlu
0000-0001-5464-2891
Türkiye

Yayımlanma Tarihi

30 Eylül 2022

Gönderilme Tarihi

2 Haziran 2022

Kabul Tarihi

24 Temmuz 2022

Yayımlandığı Sayı

Yıl 2022 Cilt: 47 Sayı: 3

DOI

https://doi.org/10.17826/cumj.1121992

IZ

https://izlik.org/JA62UM94FL

APA

Gülcü Üstün, N. S., & Karayağmurlu, A. (2022). Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder. Cukurova Medical Journal, 47(3), 1381-1383. https://doi.org/10.17826/cumj.1121992

AMA

1.Gülcü Üstün NS, Karayağmurlu A. Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder. Cukurova Med J. 2022;47(3):1381-1383. doi:10.17826/cumj.1121992

Chicago

Gülcü Üstün, Nur Seda, ve Ali Karayağmurlu. 2022. “Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder”. Cukurova Medical Journal 47 (3): 1381-83. https://doi.org/10.17826/cumj.1121992.

EndNote

Gülcü Üstün NS, Karayağmurlu A (01 Eylül 2022) Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder. Cukurova Medical Journal 47 3 1381–1383.

IEEE

[1]N. S. Gülcü Üstün ve A. Karayağmurlu, “Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder”, Cukurova Med J, c. 47, sy 3, ss. 1381–1383, Eyl. 2022, doi: 10.17826/cumj.1121992.

ISNAD

Gülcü Üstün, Nur Seda - Karayağmurlu, Ali. “Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder”. Cukurova Medical Journal 47/3 (01 Eylül 2022): 1381-1383. https://doi.org/10.17826/cumj.1121992.

JAMA

1.Gülcü Üstün NS, Karayağmurlu A. Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder. Cukurova Med J. 2022;47:1381–1383.

MLA

Gülcü Üstün, Nur Seda, ve Ali Karayağmurlu. “Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder”. Cukurova Medical Journal, c. 47, sy 3, Eylül 2022, ss. 1381-3, doi:10.17826/cumj.1121992.

Vancouver

1.Nur Seda Gülcü Üstün, Ali Karayağmurlu. Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder. Cukurova Med J. 01 Eylül 2022;47(3):1381-3. doi:10.17826/cumj.1121992